Compare Cadila Healthcare with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ALEMBIC PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ALEMBIC PHARMA CADILA HEALTHCARE/
ALEMBIC PHARMA
 
P/E (TTM) x 28.8 16.6 173.4% View Chart
P/BV x 4.6 6.6 70.3% View Chart
Dividend Yield % 0.7 0.6 128.9%  

Financials

 CADILA HEALTHCARE   ALEMBIC PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
ALEMBIC PHARMA
Mar-19
CADILA HEALTHCARE/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs352664 53.1%   
Low Rs207412 50.1%   
Sales per share (Unadj.) Rs139.2208.7 66.7%  
Earnings per share (Unadj.) Rs11.831.0 38.0%  
Cash flow per share (Unadj.) Rs18.637.1 50.0%  
Dividends per share (Unadj.) Rs3.505.50 63.6%  
Dividend yield (eoy) %1.31.0 122.6%  
Book value per share (Unadj.) Rs101.4144.2 70.3%  
Shares outstanding (eoy) m1,023.74188.52 543.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.02.6 77.8%   
Avg P/E ratio x23.717.4 136.8%  
P/CF ratio (eoy) x15.014.5 103.8%  
Price / Book Value ratio x2.83.7 73.9%  
Dividend payout %29.817.7 167.7%   
Avg Mkt Cap Rs m286,033101,461 281.9%   
No. of employees `00013.4NA-   
Total wages/salary Rs m24,1457,467 323.4%   
Avg. sales/employee Rs Th10,632.7NM-  
Avg. wages/employee Rs Th1,801.2NM-  
Avg. net profit/employee Rs Th898.5NM-  
INCOME DATA
Net Sales Rs m142,53139,347 362.2%  
Other income Rs m1,13994 1,214.3%   
Total revenues Rs m143,67039,441 364.3%   
Gross profit Rs m24,1988,736 277.0%  
Depreciation Rs m6,9651,152 604.4%   
Interest Rs m3,418184 1,856.6%   
Profit before tax Rs m14,9547,493 199.6%   
Minority Interest Rs m28811 2,666.7%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1981,568 204.0%   
Profit after tax Rs m12,0445,844 206.1%  
Gross profit margin %17.022.2 76.5%  
Effective tax rate %21.420.9 102.2%   
Net profit margin %8.514.9 56.9%  
BALANCE SHEET DATA
Current assets Rs m87,15419,577 445.2%   
Current liabilities Rs m82,69414,896 555.1%   
Net working cap to sales %3.111.9 26.3%  
Current ratio x1.11.3 80.2%  
Inventory Days Days7190 79.6%  
Debtors Days Days9445 206.8%  
Net fixed assets Rs m133,23627,097 491.7%   
Share capital Rs m1,024377 271.6%   
"Free" reserves Rs m102,73326,811 383.2%   
Net worth Rs m103,75727,188 381.6%   
Long term debt Rs m32,1464,993 643.8%   
Total assets Rs m236,86647,778 495.8%  
Interest coverage x5.441.7 12.9%   
Debt to equity ratio x0.30.2 168.7%  
Sales to assets ratio x0.60.8 73.1%   
Return on assets %6.512.6 51.7%  
Return on equity %11.621.5 54.0%  
Return on capital %13.723.6 58.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75219,453 271.2%   
Fx outflow Rs m14,5046,065 239.2%   
Net fx Rs m38,24813,388 285.7%   
CASH FLOW
From Operations Rs m25,0548,120 308.6%  
From Investments Rs m-10,123-7,556 134.0%  
From Financial Activity Rs m-10,942590 -1,853.3%  
Net Cashflow Rs m3,9891,153 345.9%  

Share Holding

Indian Promoters % 74.8 74.1 100.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 2.9 286.2%  
FIIs % 5.9 9.1 64.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 13.9 79.1%  
Shareholders   44,069 49,328 89.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   WYETH  IPCA LABS  JUBILANT LIFE SCIENCES  NEULAND LABS  PIRAMAL ENTERPRISES  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indigo Paints IPO, India's Crude Oil Production in December, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed a sharp sell-off during closing hours yesterday and ended lower.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 21, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - SUN PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS